Literature
首页医源资料库在线期刊美国临床营养学杂志2002年76卷第3期

Bioconversion of vaccenic acid to conjugated linoleic acid in humans

来源:《美国临床营养学杂志》
摘要:oleicacidoilwasprovidedbytheRaisioGroup,Raisio,Finland。ABSTRACTBackground:Vaccenicacid(11-transoctadecenoicacid。VA),amajortransfattyacidinthefatofruminants,isproducedintherumenandconvertedintissuestorumenicacid(9-cis,11-transoctadecenoicacid。RA),an......

点击显示 收起

Anu M Turpeinen, Marja Mutanen, Antti Aro, Irma Salminen, Samar Basu, Donald L Palmquist and J Mikko Griinari

1 From the Departments of Applied Chemistry and Microbiology (AMT and MM) and Animal Science (JMG), University of Helsinki; the Biomarker Laboratory, Department of Health and Functional Capacity, National Public Health Institute (AA and IS), Helsinki; the Department of Geriatrics, Uppsala University, Uppsala, Sweden (SB); and the Department of Animal Sciences, The Ohio State University, Wooster (DLP).

2 Supported by the National Dairy Council (United States), the Dairy Research and Development Corporation (Australia), and the Dairy Farmers of Canada. The high–oleic acid oil was provided by the Raisio Group, Raisio, Finland.

3 Reprints not available. Address correspondence to AM Turpeinen, University of Helsinki, Department of Applied Chemistry and Microbiology, PO Box 27, 00014 Helsinki, Finland.


ABSTRACT  
Background: Vaccenic acid (11-trans octadecenoic acid; VA), a major trans fatty acid in the fat of ruminants, is produced in the rumen and converted in tissues to rumenic acid (9-cis, 11-trans octadecenoic acid; RA), an isomer of conjugated linoleic acid, by 9-desaturase. There are indications that this conversion also occurs in humans.

Objective: The aim of this controlled intervention was to study the conversion of VA to RA in humans after consumption of diets with increasing amounts of VA.

Design: Thirty healthy subjects consumed a baseline diet rich in oleic acid for 2 wk. The subjects were then divided into 3 groups (n = 10 per group) and provided a diet containing 1.5, 3.0, or 4.5 g VA/d for 9 d. All diets contained equal amounts of macronutrients and differed only in their fatty acid compositions. The fats were mixed into conventional foods, and nearly all food was provided during the study.

Results: The proportion of VA in serum total fatty acids increased 94%, 307%, and 620% above baseline with the 1.5-, 3.0-, and 4.5-g diets, respectively. This was associated with a linear increase in the proportion of RA. The conversion rate was 19% on average, with significant interindividual differences with all 3 intakes of VA. The urinary excretion of 8-iso-prostaglandin F2 increased in all groups (P < 0.001).

Conclusions: The results quantify the desaturation of VA to RA in humans. Conversion is likely to contribute significantly to the amount of RA available to the body, and dietary intakes of VA should thus be taken into account when predicting RA status.

Key Words: Vaccenic acid • rumenic acid • conjugated linoleic acid • trans fatty acids • endogenous synthesis • 9-desaturase • isoprostanes


INTRODUCTION  
Conjugated linoleic acid (CLA) is a collective term for isomers of linoleic acid with conjugated double bonds in several positions and conformations. CLA has received considerable interest during the past decade, because it has been shown to promote various beneficial health-related effects in animals, including anticarcinogenic and antiatherogenic effects and effects on body composition and fat metabolism (see 1 for a review).

Ruminant fat is the main dietary source of CLA (2). Consumption of milk fat correlates with CLA concentrations in plasma (3), adipose tissue (4), and human milk (5). The daily intake of CLA in Western populations has been estimated to be 50–300 mg/d. The current intake, however, is lower than intakes that have had beneficial health effects in animal studies.

Vaccenic acid (11-trans-octadecenoic acid; VA) is a major trans fatty acid in milk fat, constituting 1.7% (range: 0.4–4%) of the total fatty acid content (6). VA is also an intermediate in the biohydrogenation of polyunsaturated 18-carbon fatty acids to stearic acid in the rumen, and is the major precursor of CLA in milk fat (7). Desaturation of VA to rumenic acid (9-cis, 11-trans octadecenoic acid; RA) in tissues is catalyzed by 9-desaturase (EC 1.14.99.5) (8, 9). Bioconversion of VA to RA was shown and quantified in a recent study in mice (10). A study in humans noted that the CLA concentration in serum total lipids increases with consumption of a diet high in trans oleic acid (18:1), but the role of 9-desaturase was not confirmed in this context (11). Conversion of VA to RA in humans could substantially increase the amount of CLA available to the body.

Our aim was to confirm and quantify the conversion of VA to RA in humans. We conducted a controlled dietary intervention at 3 VA intakes in healthy humans. This design allowed us to estimate the extent to which dietary VA is converted to RA. Recent studies showed increases in the urinary excretion of lipid oxidation products after dietary CLA supplementation (12, 13). To examine whether endogenously formed CLA has a similar effect, we analyzed the urinary excretion of an indicator of arachidonic acid oxidation, 8-iso-prostaglandin F2 (8-iso-PGF2).


SUBJECTS AND METHODS  
Subjects
Thirty healthy subjects (22 women and 8 men) were recruited to the study. The subjects were screened for serum total cholesterol, triacylglycerols, blood pressure, and urinary glucose and protein. They completed a questionnaire about their dietary habits, alcohol consumption, and other lifestyle factors. The mean age of the subjects was 26 y and they were of normal weight [body mass index (BMI; in kg/m2) 19.0–25.5], were normocholesterolemic (serum total cholesterol 3.2–5.4 mmol/L), and were normotensive [blood pressure: < 140 (systolic) and < 90 mm Hg (diastolic)]. None of the subjects smoked, and 8 women used oral contraceptives. The baseline characteristics of the subjects are presented in Table 1. The study protocol was approved by the ethics committees of the University of Helsinki and the National Public Health Institute, Helsinki. The subjects gave their written consent before entering the study.


View this table:
TABLE 1 . Characteristics of subjects before the study1  
Diets
The study consisted of a 2-wk baseline period and a 9-d experimental period. The baseline diet was designed to contain negligible amounts of ruminant fats, and the intake of polyunsaturated fatty acids (PUFAs) was limited to 3% of energy. High–oleic acid sunflower oil [85% oleic acid (18:1), Elsun 85 Extra; Raisio Group, Raisio, Finland] was used throughout the study in salad dressings, cooking, and baking. A commercial margarine (Kevyt Linja; Unilever Best Foods, Helsinki) was used as a bread spread. After the baseline period, the subjects were randomly allocated into 3 groups (n = 10 per group) and were provided a diet containing 1.5, 3.0, or 4.5 g VA/d during the experimental period. Sex was not balanced among treatments: n = 0 and 10, 5 and 5, and 3 and 7 men and women in the 1.5-g, 3.0-g, and 4.5-g treatment groups, respectively.

The experimental fat was produced by Natural ASA (Hovdebygda, Norway). It was a mixture of fatty acids and contained (as a percentage of total fatty acids) 29.5% (VA), 32.1% 12-trans 18:1, 11.5% 11-cis 18:1, and 12.1% 12-cis 18:1. The fat was incorporated into desserts and bakery products.

All diets consisted of conventional solid foods and were designed to contain 30% of energy as fat, 15% as protein, and 55% as carbohydrates. A weekly rotating menu was used. On weekdays the subjects ate lunch at the Division of Nutrition, where they received the food to be consumed the rest of the day and the next morning; on Fridays they were given the food to be consumed over the weekend. Each participant’s food was weighed according to their energy level. Energy level was determined before the study began by using calculated surface area (14), age, and self-reported physical activity. Body weight in light clothing was recorded biweekly, and energy intake was adjusted to avoid weight changes.

In addition to the food supplied, which provided 90% of the daily energy intake, the subjects were allowed to choose a limited amount of fat- and cholesterol-free food items daily to provide the remaining 10% of daily energy intake. The participants kept diaries in which they recorded the foods they selected, the amount of free-choice foods eaten, any signs of illness, all medications used, and any deviation from their diets.

Duplicate portions of the diets were collected for 1 wk and homogenized. Before homogenization, 5 g butyl hydroxytoluene/kg (Merck, Germany) was added to prevent oxidation. The homogenized samples were freeze-dried and analyzed for total fat and nitrogen contents at the Agricultural Research Center of Finland, Jokioinen, and for fatty acid composition at the National Public Health Institute, Helsinki. The analyzed values were combined with the values calculated from the free-choice foods.

Blood and urine sampling
Fasting venous blood samples were collected with minimal stasis between 0730 and 1000 at the end of the baseline period (day 0) and on 4 mornings (days 2, 4, 6, and 9) during the experimental period. The blood samples for each subject were taken at the same time of the morning throughout the study.

Two 24-h urine samples were collected at the end of the baseline and experimental periods with the use of a Japanese aliquot cup (KK Izumi Seisakusyo Co, Ltd, Japan). The urine samples were divided into aliquots and stored at -70 °C. Urinary isoprostanes were analyzed from pooled individual samples from each period.

Serum total lipids and VLDLs
Serum total lipids were extracted and methylated as described by Folch et al (15) and Stoffel et al (16). Methylation was done with 1% H2SO4 in dry methanol. In our preliminary studies we found that 1% provides sufficient methylation but does not cause isomerization of CLA to a significant extent. The percentile distribution of methylated fatty acids was determined by gas chromatography (GC; model 6890 with the use of workstation software A.06.01; Hewlett-Packard, Palo Alto, CA) with a 60-m Supelco SP 2380 column (Supelco, Inc, Bellefonte, PA) and hydrogen as carrier gas. Fatty acid peaks from 14:0 to 22:6 were identified in a temperature-programmed run. Interassay variation was 0.5–2% for GC peaks > 1% and 1.5–5% for peaks < 1%. For RA, variation was 3%. The column does not separate 10-trans 18:1 and 11-trans 18:1 (VA) isomers. However, the baseline diet contained negligible amounts of both 10-trans and VA and there were no 10-trans isomers in the experimental fat. Thus, the 10–11-trans peak is referred to as VA.

VLDL was isolated from fresh serum samples by ultracentrifugation at a density of < 1.019 g/L (100 000 rpm, 3 h, and 5 °C) according to the method of Havel et al (17). A Beckman model L preparative centrifuge (Beckman Instruments, Inc, Palo Alto, CA) with a type TFT 45.6 rotor (Kontron Instruments, Zürich) was used, and the solution densities were adjusted with potassium bromide. The lipoprotein fraction was removed with the use of a standard tube-slicing technique (Spinco Tube Slicer; Beckman; 18) and stored at 4 °C. VLDL-triacylglycerol fatty acids were separated by thin-layer chromatography (19). Fatty acids were methylated and determined by GC as described for serum total fatty acids. VLDL triacylglycerols were further analyzed with Ag+ HPLC to separate 7-trans, 9-cis, and 9-cis, 11-trans CLA isomers (20).

Urinary isoprostanes
8-iso-PGF2, a major isoprostane and an indicator of nonenzymatic arachidonic acid oxidation, was analyzed from unextracted urine samples with the use of radioimmunoassay (21). In brief, an antibody raised in rabbits by immunization with 8-iso-PGF2 was used. The cross-reactivities of the antibody with 8-iso-15-keto-13,14-dihydro-PGF2; 8-iso-PGF; PGF2; 15-keto-PGF2;15-keto-13,14-dihydro-PGF2; thromboxane B2; 11-ß-PGF2; 9-ß-PGF2; and 8-iso-PGF3 were 1.7%, 9.8%, 1.1%, 0.01%, 0.01%, 0.1%, 0.03%, 1.8%, and 0.6%, respectively. The detection limit of the assay was 23 pmol/L. Intraassay mean values for the low and high spiked standards in the human plasma are 95.6% and 101%, respectively. Intraassay CVs of the low and high standards in the human plasma are 14.5% and 12.2%, respectively. The urinary concentrations of 8-iso-PGF2 were adjusted for creatinine values, which were measured with the use of a commercial kit (IL Test; Monarch Instrument, Amherst, NH).

Statistical analysis
Fatty acid data were analyzed as repeated measures according to the following model:

RESULTS  
All subjects successfully completed the study. No significant changes in body weight were observed during the study. Double-portion analysis of the baseline and experimental diets showed that the intake of macronutrients was not significantly different during the 2 periods, whereas significant differences in fatty acid composition were observed (Table 2): the baseline diet was low in VA (< 0.2 g) and the intakes of VA in the 3 experimental diets were as planned. The CLA intake from the baseline diet was also low and remained unchanged throughout the study.


View this table:
TABLE 2 . Mean daily intake of nutrients from 10-MJ baseline and experimental diets according to duplicate-portion analysis and the calculated contribution of freely selected items  
Changes in serum total fatty acid composition during the intervention are presented in Table 3 and for VA and RA in Figure 1. In all 3 groups, the proportion of VA increased until day 4, and the response was linear (P < 0.001). RA also increased and reached a plateau after day 2 in all groups, but an increase was again seen on day 9; the dose response was linear (P < 0.0001).


View this table:
TABLE 3 . Serum total fatty acids in subjects consuming diets containing 1.5, 3, or 4.5 g vaccenic acid/d1  

View larger version (23K):
FIGURE 1. . Changes in plasma vaccenic acid and conjugated linoleic acid (CLA) in subjects who consumed diets providing 1.5 g (•; n = 10), 3.0 g (; n = 10), or 4.5 g (; n = 10) vaccenic acid daily.

 
VLDL triacylglycerols (data not shown), measured on days 0, 4, and 9 in the group who consumed 3.0 g VA/d, showed a pattern for VA and RA that was similar to the pattern seen in serum total fatty acids. Although the proportion of VA had reached a plateau by day 4 and thereafter decreased slightly, RA still showed an upward trend.

Use of the slope of the linear regression RA versus VA + RA as an estimate of conversion gave an average conversion rate of 19% (Figure 2). This approach is valid because the dietary supply of CLA was small and constant (Table 2); therefore, any increase in plasma RA could occur only by desaturation of dietary VA. Significant interindividual differences were observed in the conversion rate: 2- to 3-fold differences in total increases in plasma RA were seen in all groups. In the 1.5-g group, one subject was a nonresponder (ie, no significant change in RA was seen, although serum VA increased). Four subjects in the 4.5-g group were identified as low responders (ie, those with an average increase in VA, but an increase in RA > 25% below the average) (Figure 2).


View larger version (11K):
FIGURE 2. . Linear regression between the change in conjugated linoleic acid (CLA) and the change in vaccenic acid (VA) + CLA in plasma total fatty acids in subjects who consumed 1.5 g (•; n = 10), 3.0 g (; n = 10), or 4.5 g (; n = 10) vaccenic acid daily. The slope represents the percentage conversion. y = 0.1906x - 0.0081.

 
No significant differences in serum fatty acids, except in VA and RA, were observed between the 3 groups (Table 3). Quadratic effects of sample day were seen for several fatty acids. However, none of the trends were large or influenced the data importantly. No changes were seen in the concentration of the 7-trans, 9-cis CLA isomer (data not shown), which coelutes with RA on GC. The 7-trans, 9-cis CLA isomer represented only a minimal proportion (5%) of the RA peak throughout the study.

The urinary excretion of 8-iso-PGF2 increased significantly from baseline (P < 0.001) in all 3 groups (0.294 to 0.468, 0.243 to 0.457, and 0.339 to 0.560 nmol/mmol creatinine in the 1.5-, 3.0-, and 4.5-g groups, respectively), representing 59%, 88%, and 65% increases, respectively. No significant differences between groups (P = 0.147) and no correlation between serum RA and urinary 8-iso-PGF2 was found.


DISCUSSION  
We showed that VA was desaturated to RA in humans and that a linear increase in serum RA was associated with increases in serum VA.

The existence of 9-desaturase, an enzyme that desaturates saturated fatty acids to monounsaturated fatty acids (eg, palmitic to palmitoleic acid and stearic acid to 18:1) was first identified in rats > 25 y ago (22) and thereafter in mice, bovines, and chickens (23). It was later shown that the same enzyme is also responsible for the conversion of VA to RA (8, 9). To quantify 9-desaturase activity and the conversion of VA to RA, pure VA was fed to mice in a recent study (10). Eleven percent of dietary VA was converted to RA, as assessed by carcass analysis. Of the VA absorbed and stored, 51% was converted. Also, in lactating dairy cows, 64% of the CLA in milk fat was estimated to be of endogenous origin (7).

A similar pathway for desaturation of VA was suggested to occur in humans, whereas evidence for this has been somewhat inconsistent. No conversion was detected in 2 subjects fed a single dose of deuterium-labeled VA (7–8 g as triacylglycerol) and followed for 48 h (24). However, a recent reanalysis of the data of one subject led the authors to conclude that VA was converted to RA (25). A controlled human intervention study showed a significant accumulation of CLA (from 0.32% to 0.43% of plasma fatty acids), despite an 87% reduction in CLA intake, in serum fatty acids of 40 healthy subjects who consumed a diet rich in VA (3 g/d) for 5 wk after consumption of a diet high in dairy fat (11). In a group consuming a high–stearic acid diet after the diet high in dairy fat, serum CLA decreased from 0.34% to 0.17%.

Consistent with the results of our preliminary study in 3 volunteers (data not shown), serum VA and RA reached a plateau after 2–4 d in the present study. However, we observed an increase in serum RA again on the last day (day 9) of the study in all groups. An increase in VLDL triacylglycerols was also seen, indicating that the increase was not due to enrichment of RA in serum pools with slower turnover rates, such as phospholipids or cholesterol esters. The reason for this increase in unknown, but we cannot exclude the possibility of a "weekend effect" because the last sample was taken on a Monday morning. Although the subjects were given instructions on when to eat the desserts and bakery products containing VA, eating habits during the weekend may have been slightly different from those adopted on weekdays.

Although slight changes in serum saturated fatty acids and in long-chain PUFAs were seen during the study, significant differences between the 3 groups were observed only in VA and RA. Because the proportion of 7-trans, 9-cis CLA separated from RA by Ag+ HPLC remained unchanged, it was concluded that appreciable amounts of 7-trans 18:1 were not present in the diet to be desaturated to 7-trans, 9-cis CLA and did not contribute to changes in the RA peak.

The conversion rate over the range of VA intakes studied was 19%. Interindividual differences were prominent, ranging from one nonresponder in the 1.5-g group to a conversion rate > 30% in another subject. The finding of 4 low responders in the 4.5-g group suggests that the enzyme became saturated in some individuals. However, because ruminant fat contains 2–3 times more VA than RA (26, 27), even low rates of conversion contribute significantly to body CLA status. The present data suggest that the total contribution of ruminant fat to body CLA status is likely to be on average 1.5 times the CLA content because of endogenous synthesis from VA.

The distribution of 9-desaturase activity in human tissues is unknown. Liver is the principal tissue for fatty acid synthesis in humans and presumably also has the highest 9-desaturase activity. It has been postulated that CLA might also be synthesized from linoleic acid through anaerobic microbial activity in the large bowel (28). However, a diet rich in linoleic acid (safflower oil) did not increase plasma CLA in humans, suggesting that it is unlikely that synthesis in the bowel would have a significant contribution to body CLA status (29).

Dietary factors may significantly affect desaturase activity. In animals, dietary PUFAs suppress 9-desaturase activity (30), whereas cholesterol (31), carbohydrates (32), and a fat-free diet (33) are known to increase the activity. In mice, increasing dietary PUFAs from 4% to 10% decreased the desaturation of VA to RA by 30% (10). In the present study, the baseline and experimental diets were designed to provide similar intakes of cholesterol, and the intake of PUFAs was limited to 3% of energy (7–8 g/d).

Early studies suggest that antioxidant activity could explain the anticarcinogenic (34, 35) and antiatherogenic (36) effects of CLA, but several, although not all (37), recent studies have shown the susceptibility of CLA to in vitro oxidation to be comparable with or higher than that of linoleic acid (38–41). The anticarcinogenic effects and cytotoxicity of CLA in cancer cell lines may be partly due to increased lipid oxidation (42, 43). Isoprostanes are formed in the body from PUFAs via nonenzymatic pathways, in contrast with eicosanoids, which are formed via enzymatic pathways. Isoprostanes are seen as in vivo indicators of lipid oxidation because increased synthesis was reported in a variety of clinical conditions associated with oxidative stress (44). Two recent studies in humans showed increased excretion of isoprostanes after CLA feeding (12, 13). Urinary 8-iso-PGF2 (a product of the nonenzymatic peroxidation of arachidonic acid) and 15-keto-dihydro-PGF2 (a product of the enzymatic peroxidation of arachidonic acid) both increased after daily CLA supplementation (4.2 g/d, containing equal amounts of the 9-cis, 11-trans and 10-trans, 12-cis CLA isomers) of healthy subjects for 3 mo (12). Enhancement in urinary isoprostanes was also seen in middle-aged men with abdominal obesity after only 1 mo of consuming mixed isomers of CLA (4.2 g/d) (13). Isoprostane concentrations returned to baseline 2 wk after the cessation of CLA intake. In agreement with the results of Basu et al (12, 13), we observed an increase in the urinary excretion of 8-iso-PGF2 in all groups with intake of mixed isomers of CLA, although not as pronounced as in the aforementioned studies. This suggests that the effects of exogenously (dietary) and endogenously formed CLA on isoprostane production are not different

The intake of CLA in Western populations is too low to provide the beneficial effects observed in animal studies. However, data from the present study warrant a reevaluation of the amount of CLA available to the body and indicate that the dietary intake of VA should also be taken into account when predicting CLA status. Conversion of VA to RA by 9-desaturase probably contributes significantly to CLA status.


ACKNOWLEDGMENTS  
We thank the kitchen personnel for excellent technical assistance, the subjects for cooperation, Matti Jauhiainen (National Public Health Institute) for the ultracentrifuge procedures, and Norman St-Pierre (The Ohio State University) for advice on statistical analyses.


REFERENCES  

  1. Banni S, Martin JC. Conjugated linoleic acid and metabolites. In: Sebedio JL, Christie WW, eds. Trans fatty acids in human nutrition. Dundee, United Kingdom: The Oily Press, 1998:261–302.
  2. Ritzenthaler KL, McGuire MK, Falen R, Shultz TD, Dasgupta N, McGuire MA. Estimation of conjugated linoleic acid intake by written dietary assessment methodologies underestimates actual intake evaluated by food duplicate methodology. J Nutr 2001;131:1548–54.
  3. Huang YC, Luedecke LO, Schultz TD. Effect of cheddar cheese consumption on the plasma conjugated linoleic acid concentration in men. Nutr Res 1994;14:373–86.
  4. Jiang J, Wolk A, Vessby B. Relation between the intake of milk fat and the occurrence of conjugated linoleic acid in human adipose tissue. Am J Clin Nutr 1999;70:21–7.
  5. Park Y, McGuire MK, Behr R, McGuire MA, Evans MA, Schultz TD. High-fat dairy product consumption increases 9c,11t-18:2 (rumenic acid) and total lipid concentrations of human milk. Lipids 1999;34:543–9.
  6. Precht D, Molkentin J. Rapid analysis of isomers of trans-octadecenoic acid in milk fat. Int Dairy J 1996;6:791–809.
  7. Griinari JM, Corl BA, Lacy SH, Chouinard PY, Nurmela KVV, Bauman DE. Conjugated linoleic acid is synthesized endogenously in lactating dairy cows by delta-9-desaturase. J Nutr 2000;130:2285–91.
  8. Mahfouz MM, Valicenti AJ, Holman RT. Desaturation of isomeric trans-octadecenoic acids by rat liver microsomes. Biochim Biophys Acta 1980;618:1–12.
  9. Pollard MR, Gunstone FD, James AT, Morris LJ. Desaturation of positional and geometric isomers of monoenoic fatty acids by microsomal preparations from rat liver. Lipids 1980;15:306–14.
  10. Santora JE, Palmquist DL, Roehrig KL. Vaccenic acid is desaturated to conjugated linoleic acid in mice. J Nutr 2000;130:208–15.
  11. Salminen I, Mutanen M, Jauhiainen M, Aro A. Dietary trans fatty acids increase conjugated linoleic acid levels in human serum. J Nutr Biochem 1998;9:93–8.
  12. Basu S, Smedman A, Vessby B. Conjugated linoleic acid induces peroxidation in humans. FEBS Lett 2000;468:33–6.
  13. Basu S, Riserus U, Turpeinen A, Vessby B. Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity. Clin Sci 2000;99:511–6.
  14. Pike RL, Brown ML. Nutrition—an integrated approach. 3rd ed. New York: Macmillan Publishing Co, 1984:736–94.
  15. Folch J, Lees M, Sloan-Stanley GHS. A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497–509.
  16. Stoffel W, Chu F, Ahrens EH Jr. Analysis of long-chain fatty acids by gas-liquid chromatography. Anal Chem 1959;31:307–8.
  17. Havel RJ, Eder HA, Bragdon JH. The determination and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345–53.
  18. Caslake MJ, Packard CJ. The use of ultracentrifugation for the separation of lipoproteins. In: Rifai N, Warnick GR, Dominiczak MK, eds. Handbook of lipoprotein testing. Washington, DC: AACC Press, 2000:625–46.
  19. Valsta LM, Salminen I, Aro A, Mutanen M. -Linolenic acid in rapeseed oil partly compensates for the effect of fish oil restriction on plasma long chain n-3 fatty acids. Eur J Clin Nutr 1996;50:229–35.
  20. Sehat N, Yurawecz MP, Roach JAG, Mossoba MM, Kramer JKG, Ku YA. Silver-ion high-performance liquid chromatographic separation and identification of conjugated linoleic acid isomers. Lipids 1998;33:217–21.
  21. Basu S. Radioimmunoassay of 8-iso-prostaglandin F2: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998;58:319–25.
  22. Strittmatter P, Spatz L, Corcoran D, Rogers MJ, Setlow B, Redline R. Purification and properties of rat liver microsome stearyl coenzyme A desaturase. Proc Natl Acad Sci U S A 1974;71:4565–9.
  23. Tocher DR, Leaver MJ, Hodgson PA. Recent advances in the biochemistry and molecular biology of fatty acyl desaturases. Prog Lipid Res 1998;37:73–117.
  24. Emken EA, Rohwedder WK, Adlof RO, DeJariais WJ, Gulley RM. Absorption and distribution of deuterium-labeled trans- and cis-11-octadecenoic acid in human plasma and lipoprotein lipids. Lipids 1986;21:589–95.
  25. Adlof RO, Duval S, Emken EA. Biosynthesis of conjugated linoleic acid in humans. Lipids 2000;35:131–5.
  26. Precht D, Molkentin J. Effect of feeding on conjugated cis-9, trans-11 octadecadienoic acid and other isomers of linoleic acid in bovine milk fats. Nahrung 1997;41:330–5.
  27. Griinari JM, Bauman DE. Biosynthesis of conjugated linoleic acid and its incorporation into meat and milk in ruminants. In: Yurawecz MP, Mossoba MM, KramerJKG, Pariza MW, Nelson GJ, eds. Advances in conjugated linoleic acid research. Champaign, IL: AOCS Press, 1998:180–200.
  28. Kepler CR, Hirons KP, McNeill JJ, Tove SB. Intermediates and products of the biohydrogenation of linoleic acid of linoleic acid by Butyrvibrio fibrisolvens. J Biol Chem 1966;241:1350–4.
  29. Herbel BK, McGuire MK, McGuire MA, Schultz TD. Safflower oil consumption does not increase plasma conjugated linoleic acid concentrations in humans. Am J Clin Nutr 1998;67:332–7.
  30. Ntambi JM. The regulation of stearoyl-CoA desaturase (SCD). Prog Lipid Res 1995;34:139–50.
  31. Landau JM, Sekowski A, Hamm MW. Dietary cholesterol and the activity of stearoyl CoA desaturases in rats: evidence for an indirect regulatory effect. Biochim Biophys Acta 1997;1345:349–57.
  32. Jeffcoat R, James AT. Interrelationship between the dietary regulation of fatty acid synthesis and the fatty acyl-CoA desaturases. Lipids 1977;12:469–73.
  33. Ntambi JM. Dietary regulation of stearoyl-CoA desaturase 1 gene expression in mouse liver. J Biol Chem 1992;267:10925–30.
  34. Ha YL, Storkson J, Pariza MW. Inhibition of benzo(a)pyrene-induced mouse forestomach neoplasia by conjugated dienoic derivatives of linoleic acid. Cancer Res 1990;50:1097–101.
  35. Ip C, Chin SF, Scimeca JA, Pariza MW. Mammary cancer prevention by conjugated dienoic derivative of linoleic acid. Cancer Res 1991;51:6118–24.
  36. Lee KN, Kritchevsky D, Pariza MW. Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis 1994;108:19–25.
  37. Jiang J, Kamal-Eldin A. Comparing methylene blue-photosensitized oxidation of methyl-conjugated linoleate and methyl linoleate. J Agric Food Chem 1998;46:923–7.
  38. Van den Berg JJM, Cook NE, Tribble DL. Reinvestigation of the antioxidant properties of conjugated linoleic acid. Lipids 1995;30:599–605.
  39. Yang L, Leung LK, Huang Y, Chen Z-Y. Oxidative stability of conjugated linoleic acid isomers. J Agric Food Chem 2000;48:3072–6.
  40. Chen ZY, Chan PT, Kwan KY, Zhang A. Reassessment of the antioxidant activity of conjugated linoleic acids. J Am Oil Chem Soc 1997;74:749–53.
  41. Zhang A, Chen ZY. Oxidative stability of conjugated linoleic acid relative to other polyunsaturated fatty acids. J Am Oil Chem Soc 1997;74:1611–3.
  42. Schonberg S, Krokan HE. The inhibitory effect of conjugated dienoic derivatives (CLA) of linoleic acid on the growth of human tumor cell lines is in part due to increased lipid peroxidation. Anticancer Res 1995;15:1241–6.
  43. O’Shea M, Devery R, Lawless F, Murphy J, Stanton C. Milk fat conjugated linoleic acid (CLA) inhibits growth of human mammary MCF-7 cells. Anticancer Res 2000;20:3591–601.
  44. Roberts LJ, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505–13.
Received for publication July 2, 2001. Accepted for publication September 19, 2001.


作者: Anu M Turpeinen
医学百科App—中西医基础知识学习工具
  • 相关内容
  • 近期更新
  • 热文榜
  • 医学百科App—健康测试工具